OncoMatch/Clinical Trials/NCT06349889
Adebrelimab and Chemoradiotherapy in High-risk LANPC
Is NCT06349889 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Adebrelimab for nasopharyngeal carcinoma.
Treatment: Adebrelimab — This trial aims to study the role of Adebrelimab combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) for high-risk locoregionally advanced nasopharyngeal carcinoma(LANPC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage IVA+T3N2M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
neutrocyte count ≥1.5×10e9/L, hemoglobin ≥90g/L, platelet count ≥100×10e9/L
Kidney function
creatinine clearance rate ≥ 60 ml/min (Cockcroft-Gault formula)
Liver function
ALT/AST ≤2.5×ULN, bilirubin ≤1.5×ULN
Adequate marrow function: neutrocyte count≥1.5×10e9/L, hemoglobin ≥90g/L and platelet count ≥100×10e9/L. ALT/AST ≤2.5×ULN, bilirubin ≤1.5×ULN. Adequate renal function: creatinine clearance rate ≥ 60 ml/min (Cockcroft-Gault formula).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06349889 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage IVA+T3N2M0 is required.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages